John Sarantopoulos, MD

John Sarantopoulos
Medical School:
University of Manitoba Faculty of Medicine - Winnipeg, Manitoba
University of Calgary, Calgary, Alberta
University of Calgary - Tom Baker Cancer Centre, Calgary, Alberta
Institute of Drug Development, San Antonio, TX
Cancer Therapy & Research Center
The University of Texas Health Science Center at San Antonio

Dr. Sarantopoulos is a clinical research investigator and medical oncologist, with a full-time faculty appointment as assistant professor of medicine in the division of hematology-oncology. His clinical interests and expertise are in early antineoplastic drug development, and evaluation for human solid tumors including genitourinary malignancies of renal, prostate, bladder, and melanoma. He is involved with CTRC’s early therapeutics phase I program and is a member of the Experimental Developmental Therapeutics Program. Dr. Sarantopoulos completed an Advance Drug Development Fellowship and is presently focusing on early phase I/II trials. He has been a co-principal investigator (PI) and PI in over 54 phase I solid tumor studies including first in human studies or first in class compounds, food effect or bioequivalence studies, drug interaction studies, QTc effect studies, and organ dysfunction studies including renal and hepatic impairment. Studies have included NCI CTEP studies and the NCI Organ Dysfunction Working Group, and Cooperative Group trials including the Southwest Oncology Group (SWOG) where he is a member of the Early Therapeutics and GU Committees, as well as industry-sponsored, and cancer center investigator-initiated trials. In addition, he has been a sub investigator in over 139 trials in this area at the CTRC over the last several years. Dr. Sarantoupolos’ education, clinical, and research experiences place him in a select group of investigators that can complete complex early phase trials that are important to the development of new treatments for patients with cancer.